References
1.     Jeyaraman P, Naithani R. Highlights of Abstracts on Hematopoietic Stem Cell Transplant in Annual Conference of ISHBT 2018.Indian J Hematol Blood Transfus. 2019 Jan;35(1):12-16.
2.     Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2020 Oct 20:1–16. doi: 10.1007/s00277-020-04297-8.
3.     Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52: e56-93.
4.     Frere P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006;37(4):411–8.
5.     Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007; 40:63–70.
6.     Dandoy CE, Ardura MI, Papanicolaou GA, Auletta JJ. Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis. Bone Marrow Transplant. 2017; 52:1091–106.
7.     Mendes ET, Dulley F, Basso M, et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Int J Infect Dis. 2012;16: e424–e428.
8.     Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
9.     Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S et al. Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. Open Forum Infect Dis. 2017 Mar 22;4(2): ofx050. doi: 10.1093/ofid/ofx050.
10.  Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant. 1998; 21:1231-8.
11.  Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018; 36:3043-54.
12.  Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother. 2006; 50:3216-9.
13.  Slavin MA, Worth LJ, Seymour JF, Thursky KA. Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients with Cancer-Related Immunosuppression. J Clin Oncol. 2019; 37:1139-40.
14.  Trecarichi EM, Pagano L, Martino B etal. Haematologic Malignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry—Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne (SEIFEM) group, Italy. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol 2016; 91:1076–81.
15.  https://web.emmes.com/study/bmt2/public/Definition/Definitions_of_Inf_Severity.pdf
16.  Martino R, Kerguelen A, Valcárcel D, Sureda A, Fachini L, Piñana JL, Briones J, Delgado J, Brunet S, Sierra J. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant. 2011 May;46(5):690-701. 
17.  Bansal A, Jeyaraman P, Gupta SK, Dayal N, Naithani R.  Clinical Utility of Procalcitonin in Bacterial infections in Patients Undergoing Hematopoietic Stem Cell Transplantation. Am J Blood Res 2020 Dec;10(6):339-344.
18.  Frere P, Hermanne JP, Debouge MH, de Mol P, Fillet G, Beguin Y. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant. 2004;33(7):745–9.
19.  Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H et al.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017; 96(11):1775–1792.
20.  Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al. Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone duMyelome (IFM). Blood 2010; 115(1):32–37.
21.  Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106:2258-66.
22.  Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018; 76:20–37.
23.  Ziegler M, Landsburg D, Pegues D, et al. Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients. Biol Blood Marrow Transplant. 2019; 25:1004–1010.
24.  Busca A, Cavecchia I, Locatelli F, D'Ardia S, De Rosa FG, Marmont F, et al. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012; 14:40-8.
25.  Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009; 15:47-53
26.  Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005; 353:977-87.
27.  Clemmons AB, Gandhi AS, Albrecht B, Jacobson S, Pantin J. Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation. J Oncol Pharm Pract. 2019 Mar;25(2):326-332.
28.  Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP. Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. Support Care Cancer. 2017 Aug;25(8):2593-2601. 
29.  Dixit A, Kumar N, Kumar S, Trigun V. Antimicrobial Resistance: Progress in the Decade since Emergence of New Delhi Metallo-β-Lactamase in India. Indian J Community Med. 2019 Jan-Mar;44(1):4-8.
30.  Heidenreich D, Kreil S, Nolte F, Reinwald M, Hofmann WK, Klein SA. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis. Ann Hematol. 2016 Jan;95(2):287-93.
31.  Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L et al. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017 Nov 13;65(11):1819-1828. 
32.  Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO); Gruppo Italiano Trapianto Midollo Osseo GITMO. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015 Feb;50(2):282-8.
33.  Chaves L, Tomich LM, Salomão M, Leite GC, Ramos J, Martins RR, Rizek C, Neves P, Batista MV, Amigo U, Guimaraes T, Levin AS, Costa SF. High mortality of bloodstream infection outbreak caused by carbapenem-resistant P. aeruginosa producing SPM-1 in a bone marrow transplant unit. J Med Microbiol. 2017 Dec;66(12):1722-1729.
34.  Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 2013; 12:497-505.
35.  Miles-Jay A, Butler-Wu S, Rowhani-Rahbar A, Pergam SA. Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis. Biol Blood Marrow Transplant. 2015; 21:539-45.